Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: Journal of Medical Internet Research

Date Submitted: May 25, 2020
Open Peer Review Period: May 25, 2020 - Jul 20, 2020
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Systematic and Statistical Review of COVID19 Treatment Trials

  • Juan Arturo Siordia; 
  • Michael Bernaba; 
  • Kenji Yoshino; 
  • Abid Ulhaque; 
  • Sooraj Kumar; 
  • Mario Bernaba; 
  • Edward Bergin; 

ABSTRACT

Background:

The COVID-19 pandemic produced multiple trials trying to promote certain treatments. However, the amount of studies having human controlled or randomized trials is scarce despite being important.

Objective:

The following systematic review and meta-analysis compiles the current data regarding human controlled COVID-19 treatment trials.

Methods:

An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, favipiravir, and heparin. Statistical analyzes were performed for common viral clearance endpoints whenever possible.

Results:

Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no seven-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin showed improvement with severe COVID-19 cases.

Conclusions:

Current medications do not show significant effect on COVID-19 viral clearance rates. Favipiravir shows favorable results compared to other tested medications. Heparin shows benefit for severe cases of COVID-19.


 Citation

Please cite as:

Siordia JA, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M, Bergin E

Systematic and Statistical Review of COVID19 Treatment Trials

JMIR Preprints. 25/05/2020:20503

DOI: 10.2196/preprints.20503

URL: https://preprints.jmir.org/preprint/20503

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.